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Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HDAC6 is a transcriptional
regulator of the histone deacetylase family, subfamily 2. Previous studies have shown that HDAC6
plays critical roles in transcription regulation, cell cycle progression and developmental events.
However, its biological roles in the development of HCC remain largely unexplored. In the present
study, we found that mRNA and protein levels of HDAC6 were up-regulated in HCC tissues and cell
lines. The proinﬂammatory cytokines, which were up-regulated in the human HCC microenviron-
ment, increased HDAC6 expression through a proximal NF-kappaB binding site on the HDAC6 gene
promoter. Furthermore, overexpression of HDAC6 could promote cell proliferation in HCC cell lines.
In contrast, HDAC6 knockdown using small interfering RNA inhibited cell proliferation. At the
molecular level, we demonstrated that HDAC6 could interact with p53 and attenuate its transcrip-
tional activity through promotion of its degradation. Therefore, our results suggest a previously
unknown HDAC6-p53 molecular network controlling HCC development.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction iﬁcations, including phosphorylation, acetylation and ubiquitina-Hepatocellular carcinoma (HCC) has become the ﬁfth most
common malignancy and the third most lethal neoplasm, leading
to about 600000 deaths annually due to late diagnosis and lack
of effective treatment options [1]. Recent advances suggest that a
variety of factors are associated with the pathogenesis of HCC, such
as hepatitis type B (HBV) and C (HCV) infections, nonalcoholic ste-
atohepatitis (NASH), gender, and dietary aﬂatoxin [2]. However,
the molecular mechanisms in the development of HCC remain
poorly understood. Therefore, it will be helpful to understand
HCC carcinogenesis at the molecular level and to identify novel
molecular targets for the development of more efﬁcacious thera-
peutics.p53 is a well-known tumor suppressor protein and a tran-
scriptional checkpoint that plays critical roles in cellular responses
to various stress signals [3]. The role of p53 as a tumor suppressor
is highlighted by the notion that over 50% of all tumors, including
HCC, carry inactivating mutations in the p53 gene [4]. Besides, low-
er expression of p53 is also observed in HCC, suggesting that re-
activation of p53 could be an important mechanism that helps to
prevent HCC development [5]. Moreover, recent studies indicate
that P53 could be regulated by a cascade of posttranslational mod-tion [6,7]. The ubiquitination and subsequent degradation of p53
are controlled mainly by the mouse double minute 2 protein
(Mdm2, or Hdm2 for the human ortholog), an oncogenic ubiquitin
ligase [8,9]. At the molecular level, Mdm2 functions as a ubiquitin
E3 ligase, which mediates p53 ubiquitination and proteasomal
degradation [8,9].
HDAC6 belongs to the class II histone deacetylase/acuc/apha
family [10]. Previous studies have found HDA6 to be an important
transcriptional regulator in cell cycle progression, autophagy,
developmental events and apoptosis [10–12]. However, the clinical
relevance of HDAC6 in HCC has not been examined. In the present
study, we found that HDAC6 expression was up-regulated in HCC
tissues and cell lines. Overexpression of HDAC6 promoted prolifer-
ation of hepatoma cells. Furthermore, we discovered that HDAC6
played a role in HCC development through regulation of p53 pro-
tein stability. Together, our results suggest that the inhibition of
HDAC6 might be a promising strategy for the development of
anti-HCC therapeutics.
2. Material and methods
2.1. Tissue samples
Primary hepatocellular carcinoma tissues and distant normal
liver tissues were collected from routine therapeutic surgery at
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and approved by Chongming Branch of Xinhua Hospital, Shanghai.
2.2. Cell culture
All cell lines used were purchased from The Cell Bank of Type
Culture Collection of Chinese Academy of Sciences (CAS, Shanghai),
and cultured in Dulbecco’s modiﬁed Eagle’s medium supple-
mented with 10% fetal calf serum, 100 IU/ml penicillin and
100 lg/ml streptomycin.
2.3. BrdU assays
Cell proliferation (expressed as A450) was evaluated by an en-
zyme-linked immunosorbent assay to determine the incorporation
of BrdU during DNA synthesis following the manufacturer’s
instructions (Beyotime, Shanghai, China). Brieﬂy, 2  103 cells
were plated per well onto 96-well plates. After 24 h of transfection,
cell proliferation was measured. Plates were read at A450 on a
spectrometer.
2.4. Transient transfections and Luciferase assays
The HDAC6 promoter was ampliﬁed from a human genomic
DNA template and inserted into pGL3 basic vector (Promega). A
mutant p65 binding motif was generated using a PCR mutagenesis
kit (Toyobo) with a primer (mutation sites underlined): 5’-CCATG-
CATGTACATGTTGAGCTTCGACCTG-30 and a reverse complement
primer. All the transient transfections were performed using Lipo-
fectamine 2000 (Invitrogen), according to the manufacturer’s
instructions. For luciferase reporter assays, HepG2 cells were
seeded in 12-well plates and transfected with the indicated plas-
mids. Cells were harvested 30 h after transfection. Luciferase activ-
ities were measured using the Dual Luciferase Reporter Assay
System (Promega, USA).
2.5. siRNA, RNA extraction and real-time Analysis
HepG2 Cells were seeded on 6-well plates and then transfected
with 20 nM siGENOME non-targeting siRNA or siRNA directedFig. 1. Up-regulation of HDAC6 in HCC tissues and cell lines. (A and B) mRNA and protein
in normal tissues (N) or HCC tissues (C). (C) The protein levels of HDAC6 were analyzed in
Hep3B, HuH-7 and Li-7 cells.against human HDAC6 (Dharmacon, USA). Total RNAs were iso-
lated from tissues or cells by TRIzol reagent, and reverse transcrip-
tions were performed using Takara RNA PCR kit (Takara, China)
following the manufacturer’s instructions. In order to quantify
the transcripts of the genes of interest, real-time PCR was per-
formed using a SYBR Green Premix Ex Taq (Takara, Japan) on a
Light Cycler 480 (Roche, Switzerland). The primer sequences used
are available upon request.
2.6. Immunoprecipitation
Cells were harvested, resuspended in lysis buffer containing
50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.5% TRITON
X-100 and protease inhibitors. Lysates were incubated with 10 lg
of indicated antibodies or IgG overnight at 4 C with gentle inver-
sion. Protein A/G beads were added for an additional 6 h at 4 C.
Beads containing immune complexes were washed three times
with 0.8 ml ice cold lysis buffer. Precipitates were denatured in
Laemmli sample buffer at 99 C for 10 min.
2.7. Western blot
Cells were harvested by trypsinization, lysed in Laemmli buffer
(100 mM Tris–HCl at pH 6.8, 200 mM DTT, 4% SDS [w/v], 20% glyc-
erol, 0.05% bromophenol blue), denatured for 10 min at 80 C,
sheared with an insulin syringe, and resolved on SDS/PAGE gels.
After immunoblotting, the membranes were blocked in PBS/0.1%
Tween-20 with 5% nonfat dry milk, and primary antibodies were
incubated in PBS/0.1% Tween-20 with 0.1%–5% nonfat dry milk.
Antibodies directed against p53, Mdm2, HDAC6, p21, Bax, Gadd45
were purchased from Santa Cruz Biotechnology (USA). Anti-p300
and anti-b-actin were obtained from Abcam Company (USA).
Anti-acetyl-lysine antibody (AcK) was from Cell Signaling Technol-
ogy (USA).
2.8. ChIP assays
Chromatin immunoprecipitation (ChIP) assay kits were used
(Upstate, USA). In short, HepG2 cells were ﬁxed with 1% formalde-
hyde to cross-link the proteins and DNA, after which DNA waslevels of HDAC6 were analyzed by real-time PCR (n = 36), (A) and Western blot, (B)
normal liver cells (THLE-3 cells) and several liver cancer cell lines, including HepG2,
Fig. 2. NF-jB activation up-regulates HDAC6 expression. (A and B) mRNA and protein levels of HDAC6 were analyzed by real-time PCR, (A) and Western blot, (B) in HepG2
cells treated with vehicle control (Ctrl) or TNFa (10 ng/ml), IL-1b (20 ng/ml), IL-6 (5 ng/ml). (C and D) mRNA and protein levels of HDAC6 in HepG2 cells transfected with
dominant-negative (Dn) IjBa, in the absence or presence of TNFa(10 ng/ml). (E) HepG2 cells were co-transfected with the indicated plasmids for 36 h, and the luciferase
activity was measured. (F) ChIP assays showed bound of p65 on the proximal promoter region of HDAC6 in HepG2 cells in the absence or presence of TNFa (10 ng/ml). A site
located at 3000 bp (distal), relative to the start site of transcription, was used as a negative control. Bars represent the mean ± S.E.M. values of four independent
experiments.
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bath on ice. The chromatin was then incubated and precipitated
with the indicated antibodies. The immunoprecipitated DNA frag-
ments were detected using real-time PCR analysis.
2.9. Statistical analysis
All data are presented as mean ± S.E.M. from three or four inde-
pendent experiments. Statistical differences were determined by a
two-tailed t test. Statistical signiﬁcance is displayed as ⁄(P < 0.05),
⁄⁄(P < 0.01) or ⁄⁄⁄(P < 0.001).
3. Results
3.1. Up-regulation of HDAC6 is a frequent event in HCC tissues or cells
First, we analyzed HDAC6 expression in 36 paired HCC and adja-
cent non-tumor liver tissues by way of real-time PCR (Supplemen-
tary Table 1). We found that HDAC6 was signiﬁcantlyup-regulated in cancer tissues (Fig. 1A).We then employedWestern
blot with anti-HDAC6 antibody to detect the protein expression le-
vel of HDAC6 in the clinical samples. Expression of HDAC6 was in-
creased in HCC samples (Fig. 1B and Supplementary Fig. 1). Also
several liver cell lines were analyzed by western blot. As shown in
Fig. 1C, we also observed the higher expression of HDAC6 in four li-
ver cancer cell lines (HepG2, Hep3B, HuH-7 and Li-7), compared
with a normal liver cell line (THLE-3). Therefore, our results demon-
strated that HDAC6 expression was up-regulated both in HCC tis-
sues and cell lines.
3.2. Identiﬁcation of HDAC6 as a transcriptional target of NF-jB
Numerous studies have demonstrated that inﬂammatory re-
sponses are responsible for the high rate of HCC development
[13]. Indeed, constitutively hyper-activation of NF-jB signaling
pathway has been observed in HCC tissues and cell lines [13]. To
investigate whether NF-jB mediates HDAC6 overexpression,
HepG2 cells were treated with several pro-inﬂammatory cytokines.
Fig. 3. Roles of HDAC6 on cell proliferation. (A) HDAC6 expression was determined by Western blot in HepG2 cells transfected with empty vector (Ctrl) or HDAC6. (B) The
growth curve of HepG2 cells transfected with empty vector (Ctrl) or HDAC6. (C) The cell proliferative potential (BrdU-positive cells) was determined in HepG2 cells
transfected with empty vector (Ctrl) or HDAC6. (D) HDAC6 expression was determined by western blot in HepG2 cells transfected with siRNA oligos targeting HDAC6 (6–1, 6–
2) or scramble siRNA (Ctrl). (E) The growth curve of HepG2 cells transfected with siRNA oligos targeting HDAC6 (6–1, 6–2) or with scrambled siRNA oligo (Ctrl). (F) The cell
proliferative potential (BrdU-positive cells) was determined in HepG2 cells transfected with HDAC6 or control siRNA oligos. Bars represent the mean ± S.E.M. values of four
independent experiments.
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HDAC6 mRNA levels. Protein levels of HDAC6 were also increased
(Fig. 2B). To determine whether regulation of HDAC6 was NF-jB
dependent, HepG2 cells were transfected with adenoviruses
expressing a dominant negative IjBa, which could bind to p65
and inhibit its translocation into the nucleus [14]. As a result, inhi-
bition of p65 activity by IjBa inhibited the induction of HDAC6 by
TNFa (Fig. 2C and D). Given that these results suggested that NF-jB
signaling regulates HDAC6 expression at the transcription level, we
asked whether p65 could bind to the HDAC6 promoter. Sequence
analysis of the 50 ﬂanking element of the HDAC6 gene was per-
formed using an online promoter scanning system (http://
www.cbil.upenn.edu/cgi-bin/tess/tess). Scanning the proximal
promoter of HDAC6 revealed a potential motif similar to an NF-
jB consensus site located at position 387 bp, relative to the start
site of transcription. Luciferase reporter assays showed that over-
expression of p65 could enhance the promoter activity, but not
when the binding site was mutated (Fig. 2E). Chromatin immuno-
precipitation (ChIP) analysis was then performed to assess the
in vivo association of NF-jB with the HDAC6 promoter. As shown
in Fig. 2F, p65 was found to be associated with the HDAC6 pro-
moter in HepG2 cells. Pro-inﬂammatory cytokines further pro-
moted the binding of p65 (Fig. 2F), indicating that the HDAC6
promoter contains a functional NF-jB binding site.
3.3. Effect of HDAC6 on HCC cell proliferation
To further elucidate the functional role of HDAC6 in HCC, we
transduced HepG2 with adenoviruses containing HDAC6
(Fig. 3A). HDAC6 overexpression resulted in a signiﬁcant increase
in cell number (Fig. 3B). Consistently, bromodeoxyuridine (BrdU)
analysis also conﬁrmed that HDAC6 overexpression promotes cell
proliferation (Fig. 3C). To further investigate the effect, HepG2 cells
were transfected with small interfering RNA (siRNA) targetingHDAC6. Two independent siRNA oligos showed efﬁcient HDAC6
knockdown in HepG2 cells, compared with scrambled siRNA-
transduced cells (Fig. 3D). Down-regulation of HDAC6 led to a
marked decrease in cell number and proliferation in these cells
(Fig. 3E and F). Taken together, our results suggest that HDAC6
might be an important positive regulator of cell proliferation.
3.4. HDAC6 regulation of p53 in HCC cells
The tumor suppressor p53 plays an essential role in cell growth
arrest and apoptosis in tumors. We asked whether overexpression
or knockdown of HDAC6 could affect p53 regulation. As shown in
Fig. 4A and B, overexpression of HDAC6 reduced p53 protein levels
while the mRNA level remained unchanged. Furthermore mRNA
and protein levels of downstream target genes in HepG2 cells such
as p21, Bax, and Gadd45, were also down-regulated (Fig. 4C). More
importantly, overexpression of HDAC6 also reduced DNA damage-
induced p53 accumulation and expression of p53 downstream
genes (Supplementary Fig. 5). P53-activation of a p21-luc pro-
moter-reporter gene in HepG2 cells was inhibited in response to
HDAC6 expression in a dose dependent manner (Fig. 4D). In con-
trast, HDAC6 depletion dramatically led to an accumulation of
p53 protein (Fig. 4E), without changes in its mRNA levels (data
not shown), suggesting that regulation of p53 by HDAC6 was not
at the level of transcription or RNA processing. Indeed, polyubiqui-
tination of endogenous p53 was enhanced in cells overexpressing
HDAC6 (Fig. 4F). Moreover, we obtained similar results in another
HCC cell line, HuH7 cells, showing that p53 protein levels were also
here regulated by HDAC6 (Supplementary Fig. 2A and B). Notably,
HDAC6 overexpression or p53 knockdown by its small interfering
oligos both promoted cell proliferation, suggesting that HDAC6
overexpression-caused cell proliferation is indeed partially depen-
dent on p53 down-regulation (Supplementary Fig. 3A and B). The
effect of HDAC6 overexpression on cell proliferation was slightly
Fig. 4. HDAC6 regulation of p53 in HepG2 cells. (A and B) Expression of p53 was analyzed by Western blot (A) and real-time PCR (B) in HepG2 cells transfected with empty
vector (Ctrl) or HDAC6 vector with or without MG132 (20 lM). MG132 was added to prevent p53 degradation. (C) Expression of p21, Bax and Gadd45 were analyzed by real-
time PCR and Western blot in HepG2 cells overexpressing empty vector (Ctrl) or HDAC6. (D) Activity of the p21-luc reporter gene in HepG2 cells transfected with p53 (Flag-
p53) in the absence or presence of HDAC6 (50, 100, 200 ng) or empty vector. Cell lysates were analyzed by Western blot using antibodies against Flag and HDAC6. (E)
Expression of p53 in HepG2 cells transfected with scramble control (Ctrl) or HDAC6 siRNA oligos. (F) Endogenous of p53 polyubiquitination in HepG2 cells transfected with
empty vector (Ctrl) or HDAC6. All the experiments mentioned above were performed three independent times.
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sion of HDAC6 might have additional effects relevant for cell pro-
liferation, besides its roles in down-regulating p53 protein levels.
3.5. HDAC6 promotes Mdm2-mediated degradation of p53
It has been well established that the acetyltransferase p300
functions as a coactivator for p53-dependent transcription, and
stabilizes p53 by preventing ubiquitination of the acetylated lysine
residues [6,7]. Therefore, we hypothesized that HDAC6 could inter-
fere with the interaction between p53 and p300 to block p300-
mediated acetylation of p53. To test this hypothesis, we analyzedthe interaction between p53 and p300 in HepG2 cells after infec-
tion with either empty vector or HDAC6 adenovirus. Expression
of HDAC6 did indeed block the interaction between endogenous
p53 and p300 in HepG2 cells (Fig. 5A). Consistently, HDAC6 over-
expression dramatically reduced the acetylation of p53 (Fig. 5B).
In addition, these results were also conﬁrmed in HuH-7 cells (Sup-
plementary Fig. 4A and B).
p300-Mediated acetylation of p53 by p300 is closely associated
with its stabilization. Previous studies have shown that p53 is
controlled primarily by Mdm2-mediated ubiquitination and
degradation by the proteasome. Given that p53 protein levelwas in-
versely correlated with that of HDAC6 and that the p53 mRNA level
Fig. 5. HDAC6 promotes Mdm2-mediated degradation of p53. (A) HepG2 cells were infected with empty vector (Ctrl) or HDAC6 adenovirus. 20 lM MG132 was added to
prevent p53 degradation. Endogenous p53 was immunoprecipitated (IP) from total cell lysates with anti-p53 antibodies. The amount of immunoprecipitated p300 was
determined by Western blot analysis. (B) HepG2 cells were infected with empty vector (Ctrl) or HDAC6 adenoviruses in the presence of MG132 (20 lM). The acetylation of
endogenous p53 was detected after immunoprecipitation and Western blotting with anti-acetyl-lysine antibody (AcK). (C) Endogenous interaction of HDAC6 with p53 or
Mdm2 in HepG2 cells assessed by co-immunoprecipitation. IgG indicates control immunoprecipitation with non-speciﬁc immunoglobulin. (D and E) Endogenous interaction
of p53 and Mdm2 in HepG2 cells (MG132 added) with HDAC6 overexpression or after transfection with empty vector (Ctrl) (D) or after knockdown (E) was determined. All
the experiments mentioned above were performed three independent times.
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could play a role in regulating Mdm2-mediated p53 ubiquitination
in vivo through protein–protein interactions. We ﬁrst investigated
whether HDAC6 interacted with Mdm2 and p53. As shown in
Fig. 5C, HDAC6 interacted with Mdm2 and p53 in HepG2 cells. Fur-
thermore, HDAC6 overexpression promoted the interaction of
Mdm2 and p53 (Fig. 5D), while knockdown of HDAC6 reduced their
interaction (Fig. 5E), supporting the notion that HDAC6 induces p53
degradation by inhibiting its interaction with the coactivator p300
and by enhancing its interactionwith the negative regulatorMdm2.4. Discussion
The epigenetic control of gene expression by the HDAC family
has been demonstrated to play critical roles in cancer initiation,
progression and metastasis [15]. Therefore, a number of HDAC
inhibitors were shown to inhibit proliferation and induce differen-
tiation or apoptosis in cultured tumor cells and animal models
[15,16]. Furthermore, preclinical studies suggested the efﬁcacy of
HDAC inhibitors as anticancer agents, with the greatest effects
shownwhen HDAC inhibitors were used in combination with other
therapies [17]. Therefore, a signiﬁcant amount of work still needs
to be performed to understand the roles of HDACs in cancer cells.
In the present study, we showed that HDAC6 expression was
up-regulated in HCC tissues and cell lines, at least in part, byNF-jB. NF-jB is a central transcription factor in both innate and
adaptive immunity. Also, an increasing number of studies have
shown that NF-jB is frequently constitutively activated and plays
a major role in the transcriptional activation of multiple antiapo-
ptotic and other oncogenic genes in cancer [18]. The importance
of cytokines and growth factors secreted by tumor cells, has been
well documented as a causative factor in constitutive NF-jB acti-
vation in cancer [19,20]. Our results indicated that HDAC6 is a
downstream target gene of NF-jB in HCC.p53 is regulated primar-
ily at the level of protein stability by its interacting partner, Mdm2.
Mdm2-deﬁcient mice die during early embryogenesis. This early
lethal phenotype can be totally suppressed by simultaneous inac-
tivation of p53, suggesting that the main function of Mdm2 is to
regulate p53 [21]. Thus, factors that regulate the physical interac-
tion of Mdm2with p53 will directly impact the p53 protein level in
the cell. For example, the transcription factor Yin Yang 1 (YY1), was
shown to be an important negative regulator of p53 by promoting
the assembly of the p53-Mdm2 complex [22,23]. Therefore, it will
be interesting to further investigate whether HDAC6 cooperates
with these molecules. Notably, we found that HDAC6 overexpres-
sion reduced p53 protein content in HuH-7 cells, which contain a
point mutation at p53 codon 220[24,25]. Interestingly, in HuH-7
cells, p53 protein has been shown to be expressed at increased lev-
els and have a prolonged half-life in the nucleus [25]. Moreover,
previous studies also demonstrated that other molecules such as
PTTG1, Sirt3 or Omentin-1 could regulate the proliferation of
886 G. Ding et al. / FEBS Letters 587 (2013) 880–886HuH-7 cells through regulation of p53 [26–28]. Therefore, together
with these reports, our results suggest that HDAC6 might regulate
p53 protein stability independent of this point mutation. In addi-
tion, expression levels of p21, Bax and Gadd45 were also regulated
by HDAC6 in HuH-7 cells. Increasing evidence suggests that p53
could inhibit cell proliferation and regulate its target genes
through both transcription-dependent and -independent mecha-
nisms [29,30]. Therefore, we speculate that the changes of mutant
p53 protein contents in HuH-7 cells may affect its target genes
(Supplementary Fig. 2 and 4). However, we could not exclude the
possibility that HDAC6 might regulate these genes independent
of p53. Further studies should be performed using p53 wild-type
and knockout cells to distinguish among these possibilities.
Taken together, our ﬁndings uncovered an important role for
HDAC6 in controlling HCC development via regulating p300-
mediated p53 acetylation and Mdm2-mediated ubiquitination,
suggesting that alteration of HDAC6 expression and/or activity
may be an important event during oncogenesis. Consistently,
HDAC6 expression is found to be elevated in tumors such as breast
cancer and bladder cancer [31,32], which further supports its roles
in tumorigenesis. Interestingly, during the preparation of our man-
uscript, Kanno, et al., showed that overexpression of HDAC6
contributes to accelerated migration and invasion activity of hepa-
tocellular carcinoma cells [33], while Jung, et al., demonstrated
that HDAC6 functions as a tumor suppressor by activating auto-
phagic cell death in liver cancer [34]. Their results suggested that
HDAC6 expression was down-regulated in a cohort of human
hepatocellular carcinoma (HCC) patients. At the molecular level,
HDAC6 overexpression induced Beclin 1 expression and the LC3-
II pathway through activation of c-Jun NH2-terminal kinase
(JNK). However, JNKs were reported to regulate cell proliferation
and act as oncogenes in the development of HCC [35]. In addition,
the different race of patients collected, at least in part, may lead to
the inconsistency between these studies. Therefore, the precise
roles and mechanisms of HDAC6 in HCC need to be further inves-
tigated using other models, such as liver-speciﬁc HDAC6 knockout
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